Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 3, pp 529–533

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

  • Yoon Jae Kim
  • Seungmin Bang
  • Jeong Youp Park
  • Seung Woo Park
  • Jae Bock Chung
  • Si Young Song
Original Article

Abstract

Purpose

There is no effective salvage regimen for failed gemcitabine-based chemotherapy. This study evaluated the efficacy and toxicity of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.

Methods

Between January 2004 and December 2007, 28 patients with pancreatic cancer previously treated with gemcitabine-based chemotherapy were enrolled. 5-Fluorouracil 1,000 mg/m2 was infused (days 1, 2, and 3) and paclitaxel 175 mg/m2 (day 1) was administered every 4 weeks. The primary endpoint of this study was efficacy and toxicity and the secondary endpoint was time to progression and overall survival.

Results

A total of 75 cycles were given, for a mean of 2.68 cycles per patient. The response could be evaluated in 20 patients. Two patients (10%) obtained a partial response, and four patients (20%) had stable disease. The median time to progression and overall survival was 2.5 and 7.6 months, respectively.

Grade 3/4 hematological toxicity included neutropenia in six patients (21.4%), anemia in one (3.6%), and thrombocytopenia in one (3.6%). One (3.6%) patient experienced grade 4 neuropathy, and two (7.2%) patients experienced grade 3 diarrhea.

Conclusion

The 5-fluorouracil and paclitaxel combination treatment seems to be effective in patients with advanced pancreatic cancer that did not respond to a gemcitabine-based regimen.

Keywords

Pancreatic cancer Paclitaxel 5-Fluorouracil Gemcitabine 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Yoon Jae Kim
    • 1
  • Seungmin Bang
    • 1
  • Jeong Youp Park
    • 1
  • Seung Woo Park
    • 1
  • Jae Bock Chung
    • 1
  • Si Young Song
    • 1
    • 2
  1. 1.Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of GastroenterologyYonsei University College of MedicineSeoulSouth Korea
  2. 2.Brain Korea 21 Project for Medical ScienceYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations